TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Opioid dependence remains a major driver of death and disease worldwide
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Subscribe To Our Newsletter & Stay Updated
